Wall Street brokerages forecast that ADMA Biologics Inc (NASDAQ:ADMA) will post earnings of ($0.35) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for ADMA Biologics’ earnings, with estimates ranging from ($0.39) to ($0.31). ADMA Biologics posted earnings per share of ($0.55) in the same quarter last year, which would suggest a positive year over year growth rate of 36.4%. The firm is scheduled to issue its next earnings results on Friday, August 10th.

According to Zacks, analysts expect that ADMA Biologics will report full-year earnings of ($1.35) per share for the current fiscal year, with EPS estimates ranging from ($1.50) to ($1.24). For the next year, analysts anticipate that the business will post earnings of ($0.23) per share, with EPS estimates ranging from ($0.36) to $0.00. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that that provide coverage for ADMA Biologics.

ADMA has been the topic of a number of research analyst reports. Maxim Group set a $8.00 price target on ADMA Biologics and gave the stock a “buy” rating in a report on Monday, March 5th. ValuEngine raised ADMA Biologics from a “strong sell” rating to a “sell” rating in a report on Saturday, April 7th. Finally, LADENBURG THALM/SH SH lowered their price target on ADMA Biologics to $7.50 and set a “buy” rating on the stock in a report on Wednesday.

NASDAQ ADMA traded up $0.08 during trading hours on Friday, reaching $4.87. The company’s stock had a trading volume of 15,714 shares, compared to its average volume of 141,609. The company has a current ratio of 4.92, a quick ratio of 3.60 and a debt-to-equity ratio of 1.76. ADMA Biologics has a 1 year low of $2.01 and a 1 year high of $5.70. The stock has a market cap of $210.27 million, a PE ratio of -2.55 and a beta of 2.11.

In other news, CEO Adam S. Grossman acquired 52,301 shares of the firm’s stock in a transaction dated Friday, June 8th. The shares were acquired at an average cost of $4.78 per share, with a total value of $249,998.78. Following the acquisition, the chief executive officer now directly owns 32,527 shares of the company’s stock, valued at $155,479.06. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Jerrold B. Grossman acquired 20,921 shares of the firm’s stock in a transaction dated Friday, June 8th. The shares were purchased at an average cost of $4.78 per share, for a total transaction of $100,002.38. Following the completion of the acquisition, the director now directly owns 98,007 shares in the company, valued at $468,473.46. The disclosure for this purchase can be found here. Insiders have bought a total of 78,222 shares of company stock worth $373,901 over the last ninety days. Insiders own 16.90% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. raised its holdings in shares of ADMA Biologics by 59.5% during the 1st quarter. BlackRock Inc. now owns 40,536 shares of the biotechnology company’s stock worth $186,000 after acquiring an additional 15,115 shares in the last quarter. Spark Investment Management LLC purchased a new stake in shares of ADMA Biologics during the 1st quarter worth approximately $102,000. Element Capital Management LLC purchased a new stake in shares of ADMA Biologics during the 1st quarter worth approximately $118,000. Iguana Healthcare Management LLC increased its position in shares of ADMA Biologics by 6.2% during the 4th quarter. Iguana Healthcare Management LLC now owns 600,000 shares of the biotechnology company’s stock valued at $1,926,000 after purchasing an additional 35,000 shares during the last quarter. Finally, JPMorgan Chase & Co. bought a new position in shares of ADMA Biologics during the 1st quarter valued at approximately $182,000. 37.42% of the stock is currently owned by institutional investors and hedge funds.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Get a free copy of the Zacks research report on ADMA Biologics (ADMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.